Stereotaxis (STXS) vs Utah Medical Products (UTMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Utah Medical Products (UTMD) has outperformed Stereotaxis (STXS) over the past year, gaining 18.4% versus a loss of 67.1%. Over five years, UTMD leads with a -17.2% price change compared with -81.3% for STXS. Utah Medical Products is the larger company by market cap ($236.6 million vs $111.2 million), about 2.1 times the size.
Utah Medical Products pays a dividend yielding 1.66%, while Stereotaxis does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STXS | UTMD |
|---|---|---|
| Share price | $1.11 | $74.54 |
| Market cap | $111.22M | $236.58M |
| 1-day change | 0.00% | +0.90% |
| YTD return | -51.74% | +33.20% |
| 1-year return | -67.06% | +18.45% |
| 5-year return | -81.28% | -17.20% |
| P/E ratio (TTM) | — | 22.73 |
| EPS (TTM) | $-0.24 | $3.28 |
| Dividend yield | 0.00% | 1.66% |
| Annual dividend | $0.00 | $1.24 |
| 52-week high | $3.42 | $76.89 |
| 52-week low | $1.09 | $53.66 |
| Distance from 52-week high | -67.54% | -3.06% |
| Analyst consensus | none | — |
| Avg. price target upside | +170.27% | — |
| Average volume | 808.41K | 34.56K |
| Shares outstanding | 100.20M | 3.17M |
| Employees | 131 | 140 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Utah Medical Products is about 2.1 times larger than Stereotaxis by market value ($236.58M vs $111.22M).
- UTMD has outperformed STXS by 85.5 percentage points over the past year.
- Utah Medical Products offers a meaningfully higher dividend yield (1.66% vs 0.00%).
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
About Utah Medical Products
UTMD stock →Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally.
Health Care · Medical/Dental Instruments · 140 employees
STXS vs UTMD FAQ
Which is bigger, Stereotaxis or Utah Medical Products?
Utah Medical Products (UTMD) is larger, with a market capitalization of $236.58M compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, STXS or UTMD?
UTMD returned +18.45% over the past 12 months, compared with -67.06% for STXS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Stereotaxis or Utah Medical Products?
Utah Medical Products pays a dividend yielding 1.66%, while Stereotaxis does not currently pay a regular dividend.
Are Stereotaxis and Utah Medical Products in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for Stereotaxis and Medical/Dental Instruments for Utah Medical Products.